Laureus Capital

Impossible Cloud is a decentralized cloud platform that leverages web3 technology to deliver enterprise-grade multi-service cloud solutions for businesses. By offering faster, more affordable, and secure services than traditional hyperscalers and private clouds, it aims to transform the cloud computing landscape. The platform is designed to provide unlimited storage capacity with no hidden costs, ensuring 100% durability and availability. With a focus on B2B customers, Impossible Cloud operates on a fiat-based payment system, allowing businesses to engage without the complexities associated with tokens or cryptocurrencies. Its decentralized architecture enhances performance and efficiency by connecting users to a global network of storage hubs, facilitating effective data management for various needs, including big data, backups, and archives.

Impossible Cloud is a decentralized cloud platform that leverages web3 technology to deliver enterprise-grade multi-service cloud solutions for businesses. By offering faster, more affordable, and secure services than traditional hyperscalers and private clouds, it aims to transform the cloud computing landscape. The platform is designed to provide unlimited storage capacity with no hidden costs, ensuring 100% durability and availability. With a focus on B2B customers, Impossible Cloud operates on a fiat-based payment system, allowing businesses to engage without the complexities associated with tokens or cryptocurrencies. Its decentralized architecture enhances performance and efficiency by connecting users to a global network of storage hubs, facilitating effective data management for various needs, including big data, backups, and archives.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Impossible Cloud is a decentralized cloud platform that leverages web3 technology to deliver enterprise-grade multi-service cloud solutions for businesses. By offering faster, more affordable, and secure services than traditional hyperscalers and private clouds, it aims to transform the cloud computing landscape. The platform is designed to provide unlimited storage capacity with no hidden costs, ensuring 100% durability and availability. With a focus on B2B customers, Impossible Cloud operates on a fiat-based payment system, allowing businesses to engage without the complexities associated with tokens or cryptocurrencies. Its decentralized architecture enhances performance and efficiency by connecting users to a global network of storage hubs, facilitating effective data management for various needs, including big data, backups, and archives.